GlaxoSmithKline | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Alcon AG USD 30.35B 15M 2024-12
Almirall EUR 2.32B 14.19M 2024-06
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.05B 263.9M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Fresenius EUR 43.55B 1.18B 2024-12
Fresenius Medical Care EUR 33.57B 1.06B 2024-12
Galapagos EUR 4.14B 36.48M 2024-12
Genmab DKK 45.81B 6.15B 2024-12
Gilead Sciences USD 59B 4.47B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
GRIFOLS EUR 21.41B 1.12B 2024-12
Hikma Pharmaceutical USD 4.85B 167M 2024-06
Lonza CHF 19.73B 1.85B 2024-12
Merck EUR 50.14B 267M 2024-09
Merck USD 117.11B 426M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Novo Nordisk 397.44B 28.06B 2024-09
Orion EUR 1.63B 21.4M 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Philips EUR 28.98B 498M 2024-12
Recordati EUR 4.2B 2.87M 2024-09
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 129.76B 3.29B 2024-06
Smith & Nephew USD 10.35B 188M 2024-12
UCB EUR 17.35B 1.72B 2024-12



GlaxoSmithKline Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.